The Guidelines Group last met on 25thFebruary 2019 at the National Amyloidosis Centre, Royal Free Hospital.
The Group continues to work very closely with Myeloma UK in the development of guidelines and position statements.
The NICE myeloma guideline was published in February 2016 (It does not address any area covered by existing NICE technology appraisals which covers most treatments at induction and relapse). The aim has been to promote the NICE guideline more widely, and to that end we produced an editorial that was published in the International Journal of Laboratory Haematology in 2016.
The UKMF Guidelines Group guidelines on The Diagnosis and Management of Multiple Myeloma 2011 have now been archived on the BSH web site, as have The Supportive Care in Multiple Myeloma 2011 guidelines. The latter have been superseded to some extent by the Screening and Management of Late and Long Term Consequences of Myeloma and its Treatment 2017 guidelines (see below)
- Screening and Management of Late and Long Term Consequences of Myeloma and its Treatment (British Journal of Haematology 2017 and BSH web site).
- Use of Imaging in the Management of Patients with Myeloma (British Journal of Haematology 2017 and BSH web site).
Current work plans
The UKMF Guidelines Group is currently working on 2 new UKMF/BSH guidelines relating to the treatment of myeloma; one will centre on the treatment of newly diagnosed patients and the other will describe the treatment of relapsed and refractory patients. There are separate writing groups for each guideline, and good early progress has been made.
Plans are also in place to produce a UKMF/GPP Good Practice on the investigation and management of the monoclonal gammopathy of undetermined significance (MGUS). Work on this should begin within the next year.
Dr Simon Stern
Chair of UKMF Guidelines Group